MOMTAZEE JAMES C 4

What Happened
James C. Momtazee, a director of BridgeBio Pharma, received a total of 9,267 restricted stock units (RSUs) on June 22, 2026 — 3,990 RSUs reported as acquired and 5,277 RSUs reported as derivative awards. Each RSU represents a contingent right to one share of common stock; the awards were granted at $0.00 per share (typical for compensation grants), so no cash was paid by the insider.

Key Details

• Transaction date: June 22, 2026; Form 4 filed June 24, 2026 (timely filing).
• Grant amounts: 3,990 RSUs (direct) + 5,277 RSUs (derivative) = 9,267 RSUs total; price reported $0.00 per RSU.
• Vesting: RSUs vest in full on June 22, 2027, subject to continued service on the board (per filing footnote).
• Ownership reported: the filing notes 80,000 shares indirectly owned through the James C. Momtazee Revocable Trust (previously reported as directly owned). The RSUs are contingent and not yet issued shares.
• Footnotes: F1–F2 confirm these are RSUs under the 2021 Incentive Plan and convert 1:1 to common stock at vesting; F3 clarifies prior reporting of 80,000 trust shares; F4 references vesting timing for related options previously reported.
• Exhibit: Power of Attorney (Exhibit 24) attached.

Context
This was a compensation award (not a market purchase or sale). RSU grants are common for directors to align incentives; they do not represent immediately tradable shares until they vest and convert to common stock. Because these RSUs vest only with continued board service, they do not signal an immediate buy or sell decision by the insider.